Cancer research has seen an immense growth and advancement in recent years. There have been a number of breakthroughs throughout 2022, with a significant number of FDA approvals1 for solid tumors as well as hematological indications, which have significant implications for cancer research and treatment.
Find the FDA drug approvals in the table below:
Month | Active Pharmaceutical Ingredient | Indication | Therapy Type |
---|---|---|---|
January 2022 | Tebentafusp | Unresectable or Metastatic Uveal Melanoma | Targeted Therapy |
February 2022 | Ciltacabtagene Autoleucel | Relapsed or Refractory Multiple Myeloma | CAR T-cell Therapy |
March 2022 | Lu 177 vipivotide tetraxetan | Metastatic castration-resistant Prostate Cancer | Radioligand Therapy |
Pembrolizumab | Advanced Microsatellite instability high (MSI-H) or Mismatch repair deficient (dMMR) Endometrial Cancer | Immunotherapy | |
Nivolumab; Relatlimab | Unresectable or Metastatic Melanoma | Immunotherapy | |
Olaparib | Aadjuvant treatment of high-risk early Breast Cancer | Targeted Therapy | |
Nivolumab | Neoadjuvant nivolumab and platinum-doublet chemotherapy for early-stage Non Small Cell Lung Cancer | Targeted Therapy | |
April 2022 | Axicabtagene Ciloleucel | Second-line treatment of Large B-cell lymphoma | CAR T-cell Therapy |
May 2022 | Tisagenlecleucel | Relapsed or Refractory Multiple Myeloma | CAR T-cell Therapy |
Nivolumab | In combination with chemotherapy and Ipilimumab for first-line Esophageal Squamous Cell Carcinoma | Immunotherapy | |
Ivosidenib | Newly Diagnosed Acute Myeloid Leukemia | Targeted Therapy | |
June 2022 | Dabrafenib | Unresectable or metastatic Solid Tumors with BRAF V600E mutation | Targeted Therapy |
Lisocabtagene maraleucel | Second-line treatment of Large B-cell lymphoma | CAR T-cell Therapy | |
August 2022 | Trastuzumab deruxtecan | HER2-low Breast Cancer | Targeted Therapy |
Trastuzumab deruxtecan | HER2-mutant Non Small Cell Lung Cancer | Targeted Therapy | |
September 2022 | Durvalumab | Locally advanced or metastatic Biliary Tract Cancer | Immunotherapy |
Futibatinib | FGFR2 gene fusions or other rearrangement positive Intrahepatic Cholangiocarcinoma | Targeted Therapy | |
October 2022 | Tremelimumab | Tremelimumab in combination with durvalumab for unresectable Hepatocellular Carcinoma | Immunotherapy |
Teclistamab | Relapsed or Refractory Multiple Myeloma | Immunotherapy | |
November 2022 | Cemiplimab | In combination with platinum-based chemotherapy for Non Small Cell Lung Cancer | Immunotherapy |
Tremelimumab | In combination with Durvalumab and platinum-based chemotherapy for Non Small Cell Lung Cancer | Immunotherapy | |
Mirvetuximab soravtansine | FRα positive, platinum-resistant Ovarian Cancer | Antibody-Drug Conjugate | |
December 2022 | Olutasidenib | Acute Myeloid Leukemia with a susceptible IDH1 mutation | Targeted Therapy |
Atezolizumab | Alveolar soft part sarcoma | Immunotherapy | |
Adagrasib | KRAS G12C mutated Non Small Cell Lung Cancer | Targeted Therapy | |
Mosunetuzumab | Relapsed or Refractory Follicular lymphoma | Immunotherapy |
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-necessary | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Necessary". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
Cookie | Duration | Description |
---|---|---|
_ga | 2 Years | This cookie is installed by Google Analytics. The cookie is used to calculate visitors... |
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-advertisement | 11 months | This cookie is set by GDPR Cookie Consent. The cookie is used to store the user consent for the cookies in the category "Advertisement". |